IngredientsBromelain is a group of enzymes that break down proteins; these enzymes are found in the stem and fruit of the pineapple plant. The Latin name for pineapple is Ananas comosus L., and the ingredient is also commonly referred to as "pineapple extract."
Fruit bromelain and stem bromelain are prepared differently and contain different enzymatic compositions. The term "bromelain" usually refers to "stem bromelain." Bromelain is a mixture of different thiol endopeptidases and other components like phosphatase, glucosidase, peroxidase, cellulase, escharase, and several protease inhibitors.
Bromelain extract is a mixture of protein-digesting (proteolytic) enzymes and several other substances in smaller quantities. The proteolytic enzymes are sulfhydryl proteases; a free sulfhydryl group of a cysteine amino acid side chain is required for function.
Bromelain is a complex mixture of proteolytic enzymes, including various proteases, such as stem bromelain, fruit bromelain, and ananain. These enzymes belong to the cysteine protease family and exhibit different substrate specificities and optimal pH ranges. The composition of bromelain can vary depending on factors such as the source of extraction and processing methods.
Bromelain isolated from the stem is regarded as the most practical and therapeutically potent form, demonstrating enhanced proteolytic activity relative to its fruit-derived counterpart. Originally, bromelain was exclusively derived from Hawaiian pineapple stems, but it is now also manufactured in Taiwan, Thailand, Brazil, and Puerto Rico.
Bromelain activity occurs between pH 3 and 7. Beyond this value, it declines progressively, causing decreased absorption at higher pH values.
Bromelain is available in many commercial herbal preparations, alone and as part of multi-ingredient dietary supplements. Bromelain is typically sold as a tablet, capsule, topical cream, and as liquid extract. The most common strength of capsules and tablets is 500 mg, but other strengths may be marketed.
Bromelain is used topically (applied to the skin) as a prescription drug in the treatment of serious burns. In cooking, bromelain is used as a meat tenderizer. Bromelain's activity is typically measured and standardized using enzymatic units such as Gelatin Digesting Units (GDU) or Milk Clotting Units (MCU), though standardization methods vary across commercial preparations.
Pineapple was traditionally used for medicinal purposes in South and Central America. The history of bromelain dates back to the ancient civilizations of South America, where the pineapple plant (Ananas comosus) is native. Indigenous peoples in Central and South America, particularly in regions like the Amazon rainforest and the Caribbean, used various parts of the pineapple plant for medicinal purposes, including treating digestive issues, reducing inflammation, and healing wounds.
Although the people of Guadeloupe introduced Christopher Columbus to the fruit in 1493, Europeans did not recognize the pineapple's beneficial attributes until later. Pineapple had a long history of traditional use among the native peoples of Central and South America. They applied pineapple dressings to wounds and skin injuries to reduce inflammation, and eased stomachaches and indigestion by drinking the juice of the fruit.
The preparation methods of indigenous peoples were straightforward and consistent with the plant's available forms: fresh juice from the fruit was consumed to address gastrointestinal complaints, while pulp or sliced sections of the fruit were applied topically to skin wounds and injuries as makeshift dressings to alleviate swelling and promote healing.
The first isolation of bromelain was recorded by the Venezuelan chemist Vicente Marcano in 1891 by fermenting the fruit of the pineapple. In 1892, Russell Henry Chittenden, assisted by Elliott P. Joslin and Frank Sherman Meara, investigated the matter more completely, and called it 'bromelin'.
Bromelain was first isolated from pineapple juice in 1891 and introduced as a therapeutic supplement in 1957. Bromelain was first isolated and described in the late 19th century by researchers in Europe, who identified its proteolytic properties. Since then, bromelain has gained recognition in both traditional and modern medicine for its potential therapeutic effects.
Bromelain was first reported to be of value as an analgesic/anti-inflammatory for use in both rheumatoid arthritis and osteoarthritic patients in 1964.
The major compounds in bromelain are enzymes such as endopeptidases, phosphatases, glucosidases, peroxidases, and cellulases, and various glycoproteins.
The principal proteolytic enzymes within bromelain are cysteine proteases — most importantly stem bromelain (EC 3.4.22.32) and fruit bromelain (EC 3.4.22.33), as well as ananain (EC 3.4.22.31) and comosain. These all share the requirement for a free thiol (–SH) group at their active site for catalytic function. Bromelain contains a complex mixture of different thiols and other endopeptidases, including various protease inhibitors, glucosidase, cellulase, phosphatase, peroxidase, and escharase.
Bromelain's proteolytic activity aids in the breakdown of dietary proteins into smaller peptides and amino acids. By hydrolyzing peptide bonds within protein molecules, bromelain facilitates their digestion and absorption in the gastrointestinal tract. This property may be particularly beneficial for individuals with impaired protein digestion, such as those with pancreatic insufficiency or digestive enzyme deficiencies.
Although bromelain's mechanism of action has not been completely identified, many studies have demonstrated that it has anti-inflammatory, antimicrobial, and anticancer effects. Bromelain can activate inflammatory mediators such as IL-1β, IL-6, INF-γ, and TNF-α in mouse and human cells. Conversely, bromelain can reduce granulocyte colony-stimulating factor (G-CSF), IL-1β, IL-6, and TNF-α secretions when immune cells have already been stimulated in an inflammatory condition.
It has been shown that bromelain can inhibit nuclear factor kappa-B (NF-κB) translocation in human cancer cells by suppressing IκB phosphorylation. In addition, bromelain can block the activation of the mitogen-activated protein kinase (MAPK) pathway in raw 264.7 cells.
The pharmacological properties of bromelain are, in part, related to its arachidonate cascade modulation, inhibition of platelet aggregation, such as interference with malignant cell growth; anti-inflammatory action; fibrinolytic activity; skin debridement properties, and reduction of the severe effects of SARS-CoV-2.
By promoting fibrinolysis, bromelain may help prevent excessive blood clot formation and improve circulation. In vitro and in vivo studies demonstrate that bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities.
Bromelain exhibits antioxidant properties by scavenging free radicals and reactive oxygen species (ROS).
Bromelain has been reported to regulate angiogenic biomarkers, including vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs). By modulating angiogenic factors, bromelain may influence vascular remodeling and tissue repair processes.
A longstanding pharmacological question has been whether bromelain, as a large protein, can be absorbed intact through the gastrointestinal epithelium and exert systemic effects. Using bromelain as a model protein, researchers studied the extent of mucosal permeation in 19 healthy men. The protein was detected in plasma by immunoassay and by its proteolytic activity after oral administration. The estimated plasma half-life was 6–9 hours; after oral multidosing (3 g/day), plasma concentration reached as much as 5,000 pg/ml by 48 hours.
Bromelain is absorbed from the gastrointestinal tract in a functionally intact form; approximately 40% of labeled bromelain is absorbed from the intestine in high molecular form. In a study carried out by Castell et al., bromelain was detected to retain its proteolytic activity in plasma and was also found linked with alpha-2-macroglobulin and alpha-1-antichymotrypsin, the two antiproteinases of blood.
When formulated in antacid, oral bromelain retained substantial proteolytic activity throughout the gastrointestinal tract. Bromelain concentrations within the colon were dependent on both dose and formulation and were sufficient to remove bromelain-sensitive molecules from both leukocytes and colon epithelial cells.
The overall landscape of clinical evidence for bromelain spans several condition areas, with varying degrees of rigor. Oral bromelain has been evaluated in more than 100 clinical trials for conditions such as sinusitis, osteoarthritis, and rheumatoid arthritis, and is usually described as well tolerated and without significant side effects or adverse events. However, the quality and scale of this evidence varies considerably by indication.
This is the area of most definitive regulatory support. In 2022, the U.S. Food and Drug Administration (FDA) approved a drug product containing bromelain for topical use for debridement (removal of dead tissue or contaminants) of severe burns in adults. The product is also approved for this purpose in the European Union.
In 2012 the European Medicines Agency approved a pineapple stem-derived bromelain-based debridement concentrate of proteolytic enzymes (NexoBrid®, MediWound Ltd, Yavne, Israel) for adult deep burns. Over 10,000 patients have been successfully treated with NexoBrid® globally, including in the US.
The benefits of bromelain-based debridement are faster debridement and healing times, reduced operations, length of stay, cases of sepsis, blood transfusions, and prevention of compartment syndrome.
A 2023 systematic review and meta-analysis concluded that moderate-quality studies demonstrated the potential of oral bromelain in pain control and topical bromelain in wound care.
There is not enough high-quality research to say whether oral bromelain should be recommended for sinusitis. Some studies suggest that oral bromelain might be helpful for reducing some symptoms associated with wisdom tooth surgery.
A small number of studies have been done on the use of bromelain taken orally for reducing symptoms of sinusitis and reducing pain and swelling after wisdom tooth extraction. For other conditions, either very little research has been done or studies have only evaluated products that contain a mixture of bromelain and other ingredients, and therefore the effects of bromelain alone are unclear.
Notably, early double-blind clinical studies on sinusitis date to the late 1960s (Ryan, 1967; Taub, 1967), and a 2005 pediatric study by Braun, Schneider, and Beuth published in In Vivo examined the therapeutic use and safety of bromelain (Bromelain-POS) in children with acute sinusitis in Germany. A 2013 pilot study by Büttner et al. examined efficacy and tolerability of bromelain in patients with chronic rhinosinusitis. However, as the NCCIH notes, the overall body of evidence remains insufficient to support definitive clinical recommendations.
Recent studies have evaluated the clinical implications of bromelain in reducing postoperative inflammatory complications after third molar surgery, but the results are contrasting.
A 2019 systematic review and meta-analysis of randomized clinical trials (published in Medicina oral, patologÃa oral y cirugÃa bucal) examined the efficacy of bromelain on health outcomes after third molar surgery. One included trial, for example, administered bromelain 200 mg twice daily for 5 days following mandibular third molar removal, assessing outcomes including pain (VAS scale) and swelling (facial reference points) on days 1, 3, and 7. Removal of impacted third molars is one of the most frequent procedures in oral surgery, but is commonly associated with postoperative pain, swelling, and trismus. These complications are thought to arise from inflammatory response which is a direct and immediate consequence of the surgical procedure, and may lead to patient discomfort and negatively affect quality of life.
Bromelain is a food supplement that may provide an alternative treatment to NSAIDs for patients with osteoarthritis. Bromelain is a crude, aqueous extract obtained from both the stem and fruit of the pineapple plant, which contains a number of proteolytic enzymes and has shown potentially beneficial effects due to its anti-inflammatory and analgesic properties.
Several studies have supported the use of bromelain, either alone or in combination with other natural remedies, to relieve pain and inflammation caused by conditions such as osteoarthritis and rheumatic diseases.
A 2006 randomized, placebo-controlled pilot study by Brien et al. (published in the Quarterly Journal of Medicine) examined bromelain as an adjunctive treatment for moderate-to-severe osteoarthritis of the knee. A 2016 study reported improved WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score following 16-week treatment with bromelain for knee osteoarthritis. In clinical trials investigating the effects of bromelain on osteoarthritis, no serious adverse effects were found, although there were several cases of gastrointestinal symptoms, dry mouth, headache, fatigue, rash, and unspecified allergic reactions. In these trials, bromelain was given at doses ranging from 540 to 1890 mg daily.
Overall, while results are encouraging, trials in osteoarthritis have generally been small, of limited duration, and some have used multi-ingredient products, making it difficult to isolate bromelain's specific contribution. Larger-scale studies and further research are needed to confirm these findings and establish optimal dosing regimens and efficacy in various medical conditions.
Whether consumed as part of fresh pineapple or in supplement form, bromelain may support various aspects of digestion, including protein digestion, nutrient absorption, relief of digestive discomfort, and maintenance of gut microbiota balance.
Through its proteolytic action, bromelain may enhance the bioavailability of nutrients derived from proteins. By breaking down protein complexes into simpler forms, bromelain may facilitate the absorption of essential amino acids and peptides across the intestinal mucosa.
Numerous studies suggest that bromelain supplementation may be beneficial for individuals with inflammatory conditions of the digestive tract, including inflammatory bowel disease (IBD) and gastritis. However, the majority of this evidence is preclinical or observational; robust, well-controlled human trials are lacking in this domain.
Evidence has suggested that bromelain counteracts some of the effects of certain intestinal pathogens like Vibrio cholerae and Escherichia coli, whose enterotoxin causes diarrhea in animals. Bromelain appears to exhibit this effect by interacting with intestinal secretory signaling pathways, including adenosine 3′:5′-cyclic monophosphatase, guanosine 3′:5′-cyclic monophosphatase, and calcium-dependent signaling cascades.
One significant benefit of bromelain is that it enhances the permeability of antibiotics such as penicillin and tetracycline, thereby increasing their absorption. Taking bromelain might increase how much antibiotic the body absorbs. Taking bromelain along with some antibiotics called tetracyclines might increase effects and side effects of these antibiotics. This interaction has been documented in both human pharmacokinetic studies and is sometimes deliberately utilized to improve antibiotic tissue penetration, particularly in clinical settings.
Bromelain is most commonly used as an anti-inflammatory agent, though scientists have also discovered its potential as an anticancer and antimicrobial agent.
Bromelain's anticancer activity is specifically related to its effect on cancer cells and their microenvironment, and to the manipulation of the immune, inflammatory, and hemostatic systems. NF-κB, Cyclooxygenase-2 (COX-2), and Prostaglandin E2 (PGE2) are boosters of cancer development, and NF-κB signaling plays a significant role in many cancer types. COX-2, a multiple target gene of NF-κB, helps in the conversion of arachidonic acid into PGE2 and leads to tumor angiogenesis and progression. Proper inhibition of the action of NF-κB, COX-2, and PGE2 can be a possible treatment for carcinoma.
In vitro work on oral cancer cells demonstrated that bromelain treatment markedly reduced cell viability in a dose-dependent manner and was associated with apoptotic markers. After treatment, the viability of both Ca9-22 and SCC25 cells was markedly reduced, in a dose-dependent manner. Bromelain induced PARP and lamin A/C degradation, and generated cleavage products. Flow cytometry analysis showed that bromelain treatment significantly increased the sub-G1 population. These findings indicate that bromelain has potential as a novel, natural anticarcinogenic medicine. These findings are entirely preclinical (cell-line studies) and cannot be extrapolated to human clinical outcomes without further research.
With respect to cancer-treatment side effects, a systematic review found that bromelain supplementation was able to reduce side effects of adjuvant hormone therapy and chemotherapy, such as mucosal dryness, arthralgia, and peripheral neuropathy induced by chemotherapy — though only three studies met inclusion criteria from 239 retrieved, indicating this evidence base is very sparse.
In vitro and in vivo studies demonstrate that bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain accounts for many therapeutic benefits like the treatment of angina pectoris, bronchitis, sinusitis, surgical trauma, and thrombophlebitis, debridement of wounds, and enhanced absorption of drugs, particularly antibiotics. However, direct robust human clinical trial evidence specifically for cardiovascular endpoints is limited.
It has been reported as having positive effects on the respiratory, digestive, and circulatory systems, and potentially on the immune system. Much of this evidence, particularly for conditions such as asthma and allergic airway disease, derives from animal models. A murine study by Secor et al. (2005) demonstrated anti-inflammatory effects in an ovalbumin-induced model of allergic airway disease. Human evidence in this area remains preliminary.
The dose varies by source and medical use between 200 and 2000 mg daily.
It is recommended to administer bromelain before food, and daily dosage should be 750–1000 mg/day in divided doses.
In clinical trials investigating the effects of bromelain on osteoarthritis, bromelain was given at doses ranging from 540 to 1890 mg daily.
In the pharmacokinetic study by Castell et al. (1997) in 19 healthy men, after oral multidosing of 3 g/day, plasma concentration reached as much as 5,000 pg/ml by 48 hours, with an estimated plasma half-life of 6–9 hours.
In one third molar surgery study, the protocol used was bromelain 200 mg twice daily for 5 days postoperatively. The dose of bromelain suggested by manufacturers is 500 mg once or twice daily, but a wide range of doses are suggested. There is no standard dose that has been approved by the FDA for oral supplemental use.
About 12 g/day of bromelain can be consumed without any major side effects, according to one cited reference — though this refers to an upper tolerance estimate from older pharmacological literature, not a recommended dose, and clinical trials have operated well below this level.
Bromelain is generally recognized as safe (GRAS, according to the FDA definition), and side effects are uncommon and typically are mild degrees of abdominal discomfort and nausea.
Hypersensitivity reactions including urticaria and rash have been reported but are usually mild and resolve rapidly with discontinuation. Rare instances of anaphylaxis have been described with its use.
Studies have rarely reported results of liver enzyme testing, and most studies were for short-term use only (3 to 6 days) and included a limited number of subjects. Nevertheless, despite widespread use, there have been no reports of liver injury, jaundice, or hepatotoxicity associated with oral or topical use of bromelain. In large case series, systematic reviews, and reports from pharmacovigilance registries on liver injury due to botanical products, bromelain has not been mentioned or listed.
Even though studies have shown bromelain to have very low toxicity, its IgE-mediated allergenic potential cannot be underestimated.
Because bromelain is a protein derived from pineapple, individuals with known allergy to pineapple may be at risk for allergic reactions. Occupational sensitization to bromelain (resulting in IgE-mediated asthma and rhinitis) has been documented in workers handling concentrated enzyme preparations in industrial settings, though this is distinct from reactions to dietary pineapple or standard supplemental doses.
Little is known about whether it's safe to use bromelain during pregnancy or while breastfeeding. Information regarding safety in pregnancy and lactation is lacking.
Anticoagulants and antiplatelet agents: Bromelain may have antiplatelet effects and may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs. There is one case report of a patient experiencing minor bruising while taking bromelain with naproxen. Bromelain is thought to have antiplatelet activity. Warfarin, aspirin, clopidogrel, and heparin are the anticoagulants of primary concern given bromelain's fibrinolytic and antiplatelet activities.
Antibiotics (tetracyclines and penicillins): Taking bromelain might increase how much antibiotic the body absorbs. Taking bromelain along with some antibiotics called tetracyclines might increase effects and side effects of these antibiotics. This interaction may require dosage consideration when bromelain is co-administered with these agents, though it has also been intentionally exploited to improve antibiotic efficacy in certain contexts.
Standardization limitations: There are currently no guidelines for the purification of bromelain, which can be performed through a variety of methods. The variability in the commercially produced product and its diverse ingredients have hindered successful development. This lack of standardization means that the enzyme activity and composition of commercial bromelain products may differ substantially, complicating direct comparisons between studies and the extrapolation of clinical trial dosages to specific commercial preparations.
While research on bromelain continues to expand, further well-designed clinical trials are needed to elucidate its mechanisms of action, optimal dosing regimens, and efficacy in various medical conditions. Most existing studies were for short-term use only (3 to 6 days) and included a limited number of subjects. Long-term safety data and large-scale randomized controlled trials are generally absent for most oral supplemental indications.
Health conditions that Bromelain may help support.
Bromelain functions as a proteolytic digestive enzyme active across both the stomach's acidic and the small intestine's alkaline environments, aiding protein breakdown and alleviating digestive discomfort. Multiple studies suggest it helps reduce gastrointestinal inflammation and supports motility. It is used as a digestive aid for individuals with impaired protein digestion.
Bromelain, a cysteine protease mixture from pineapple (Ananas comosus), has demonstrated inhibition of allergic airway disease in murine asthma models and clinical benefit in human allergic rhinitis. A controlled trial of a Boswellia serrata and bromelain compound showed significant benefit in seasonal allergic rhinitis complicated by upper respiratory infections. Mechanistically, bromelain reduces eosinophilic airway inflammation and modulates dendritic cell function.
Bromelain is documented in PMC reviews to prevent or minimize the severity of angina pectoris via its fibrinolytic, antiplatelet, and antithrombotic properties. It may break down cholesterol plaques and exerts potent fibrinolytic activity, reducing thrombus formation relevant to ischemic cardiac conditions. Two large-scale clinical studies on heart patients reportedly showed near-complete elimination of thrombosis.
Bromelain inhibits NF-κB and COX-2 pathways, reduces oxidative stress markers, and has been shown to decrease oxidative stress-related inflammatory injury. PMC reviews and systematic reviews of enzyme-antioxidant therapy in arthritis confirm anti-oxidant activities. A systematic review of osteoarthritis concluded that bromelain exerts beneficial effects partly via its antioxidant properties.
Bromelain, a mixture of proteolytic enzymes from pineapple stem, has anti-inflammatory properties through fibrinolytic and cytokine-modulating mechanisms. It has been studied in combination and solo OA preparations, referenced in OA nutraceutical systematic reviews, and the Arthritis Foundation lists it among studied supplements for knee and hip OA.
Bromelain has demonstrated anti-inflammatory activity in animal models of allergic airway disease (AAD), attenuating airway inflammation and altering CD4+/CD8+ T lymphocyte ratios. It inhibits Th2 cytokines such as IL-4 and IL-13, which drive asthmatic inflammation. While direct large-scale human RCTs in asthma are lacking, preclinical and immunological evidence supports a scientifically plausible relationship.
Clinical studies show bromelain reduces exercise-induced muscle damage, delayed-onset muscle soreness (DOMS), and inflammatory markers (CRP, IL-6) post-exercise. A randomized double-blind trial in competitive cyclists found bromelain (1000 mg/day over six race days) reduced subjective fatigue and showed a trend toward maintaining testosterone concentrations compared to placebo. Bromelain's proteolytic and anti-inflammatory properties underpin these effects.
Bromelain is recommended as an adjuvant therapeutic approach in inflammatory, malignant, and autoimmune diseases. It modulates T cell surface adhesion molecules and TGF-β expression in rheumatoid arthritis and osteomyelofibrosis. Animal studies show efficacy in the experimental allergic encephalomyelitis (EAE) model of multiple sclerosis, and immunomodulatory actions on NK cells and lymphocytes are documented.
Bromelain, the proteolytic enzyme complex from pineapple, has documented anti-inflammatory properties and has been studied for reducing swelling and inflammation from insect stings and bites by enzymatically breaking down inflammatory mediators and venom proteins. It is referenced in complementary medicine literature for insect sting management.
Bromelain from pineapple has documented anticoagulant and fibrinolytic properties. It prolongs prothrombin time and APTT, increases fibrin cleavage, and upregulates antithrombin III and plasminogen. A 2022 PMC study confirmed bromelain inhibited the coagulation cascade and promoted fibrinolytic activity in a NAFLD model through LC-MS/MS-verified protein expression changes.
Bromelain, the proteolytic enzyme complex from pineapple, has demonstrated therapeutic benefits for bronchitis and sinusitis through mucolytic, anti-inflammatory, and immunomodulatory mechanisms. German Commission E recognizes bromelain for inflammation of the upper and lower respiratory tract. Evidence reviews document its efficacy for reducing sputum viscosity and bronchial inflammation.
Bromelain is the active constituent of the EMA-approved debridement agent NexoBrid® for deep burns. Multiple RCTs and systematic reviews demonstrate bromelain-based enzymatic debridement reduces time to complete debridement, lowers surgical excision rates, and improves spontaneous healing and cosmetic outcomes compared to standard care. A 2025 meta-analysis found faster debridement (MD -3.92; p<0.00001) and higher spontaneous healing rates with bromelain.
Bromelain, a proteolytic enzyme from pineapple, is explicitly cited for bursitis by ADAM, Healthgrades, and PainScale. It reduces inflammation and swelling. A 2004 review found it showed promise for OA treatment. The NIH notes bromelain may help arthritis pain combined with trypsin and rutin. Typical dosing: 500–2,000 mg three times daily between meals.
Bromelain, the proteolytic enzyme complex from pineapple stem, has anti-inflammatory and fibrinolytic effects relevant to nerve compression syndromes. It has been studied as part of a multi-ingredient supplement for early CTS, with statistically significant improvement in nerve function and sleep quality reported. WebMD notes clinical trial evidence in CTS for bromelain-containing combinations.
Bromelain, a proteolytic enzyme from pineapple, is used in oral anti-cellulite supplements for fibrinolytic and anti-inflammatory properties. It is intestinally absorbed without degradation and is an active ingredient in a commercial anti-cellulite supplement studied in a randomized double-blind clinical trial alongside aronia extract and quercetin.
Bromelain, a cysteine protease complex from pineapple stem, has documented anti-inflammatory activity supported by multiple human clinical trials and systematic reviews. Its primary mechanisms include inhibition of NF-κB and COX-2 signaling and downregulation of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and PGE-2. A 2023 PROSPERO-registered systematic review of seven RCTs found that bromelain supplementation reduced inflammatory markers in most studies, though effect consistency is limited by population heterogeneity and varying doses and durations.
Bromelain has documented analgesic properties in human clinical studies including inflammatory pain, urogenital inflammation, post-surgical pain, and chronic arthritis. It acts directly on pain mediators such as bradykinin, reduces plasma kininogen, and inhibits PGE2. Multiple PMC reviews and clinical trials confirm its use in chronic pain settings.
Multiple preclinical and emerging clinical studies demonstrate bromelain's potential in ulcerative colitis, including an animal model showing markedly decreased IBD development and severity, and anecdotal reports of remission in two UC patients. A 2025 randomized triple-blind placebo-controlled RCT in 70 UC patients evaluated bromelain on disease activity and quality of life over 8 weeks.
Bromelain is a cysteine protease mixture extracted from pineapple stem and fruit with well-documented protein-digesting activity. It survives gastric transit and has been used in combination enzyme products for pancreatic steatorrhea and dyspepsia. Animal studies show it stimulates pancreatic trypsin activity and beneficially modulates gut microbiota.
Bromelain, a protease enzyme from pineapple, has anti-inflammatory properties studied in allergic and inflammatory conditions including eczema. It is commonly co-administered with quercetin for eczema due to its ability to enhance quercetin bioavailability and its own independent anti-inflammatory effects on immune cell function.
Bromelain is a proteolytic enzyme complex derived from pineapple stem with anti-inflammatory and anti-edematous properties relevant to joint conditions. Studies show bromelain reduces pro-inflammatory markers (MMP-3, MMP-13, IL-6, PGE2) in synovial cells (PMC8515758). It has been used in European phytotherapy for joint inflammation and is listed in the German Commission E monograph for soft tissue swelling.
Bromelain, a fibrinolytic protease from pineapple, has been tested in multiple double-blind RCTs for vitreous floater reduction. Two Taiwanese RCTs (n=280 and n=224) found high-dose mixed-fruit-enzyme supplementation including 190 mg bromelain significantly reduced vitreous opacities over 3 months. A 2025 pilot RCT also included bromelain in a multi-ingredient floater supplement with significant clinical results.
Bromelain, a cysteine protease mixture from pineapple, inhibits allergic sensitization and modulates dendritic cell activity to reduce IgE-mediated responses. Animal studies show it reduces eosinophil infiltration, BAL lymphocytes, and OVA-specific IgE in allergic airway disease models. It is traditionally combined with quercetin to improve bioavailability and address food-related inflammatory responses.
Bromelain, a cysteine protease from pineapple stem, aids protein digestion and has been studied for its role in reducing gut permeability-related food sensitivity symptoms. Animal and in vitro research (PMC9696696) show bromelain modulates gut microbiota, increasing beneficial Akkermansia muciniphila and enhancing protein digestive capacity. Bromelain is used clinically in digestive enzyme blends to support breakdown of food proteins in sensitive individuals.
Bromelain's proteolytic and anti-inflammatory properties are supported by multiple studies suggesting benefit in gastritis. It may protect GI tissues from inflammatory damage by modulating cytokines and prostaglandins, and its dual activity in both acidic and alkaline pH environments makes it active throughout the upper GI tract. PMC reviews identify gastritis as an indication supported by clinical and study evidence.
Bromelain has significant preclinical and emerging clinical evidence in IBD, including a study showing marked reduction in IBD development in IL-10-knockout mice and clinical improvement signals in ulcerative colitis patients. It blocks TNF-α receptors, suppresses NF-κB, and reduces pro-inflammatory cytokines relevant to IBD pathophysiology. A 2025 RCT specifically assessed bromelain in UC disease activity and quality of life.
Bromelain, a proteolytic enzyme from pineapple stem, has demonstrated anti-edema and anti-inflammatory properties with clinical relevance to lymphedema. It breaks down fibrin contributing to tissue hardening and improves lymphatic and blood circulation, reducing swelling. Early clinical research (Wobenzym enzyme combination studies) and a PMC-indexed pilot study support its use in fibrotic and edematous conditions including post-mastectomy lymphedema.
Bromelain, a pineapple-derived proteolytic enzyme, has clinical evidence for treating primary and secondary lymphedema. A study in Lymphology (Michelini et al., 2019; n=52) using Bromelain combined with Rutin and Melilotus in lymphedema stages I–II showed significant reductions in limb swelling and tissue thickness. Bromelain reduces inflammation and fibrin deposition in lymphatic tissues.
Bromelain, proteolytic enzymes from pineapple stem, reduces mast cell-associated microclotting, modulates Th1/Th2 immune balance, and reduces eosinophil and mast cell tissue infiltration in allergic airway models. It is frequently combined with quercetin in MCAS protocols, where it also enhances quercetin bioavailability. Evidence supports its role in multi-modal mast cell and inflammatory cascade management.
Bromelain is a complex of proteolytic enzymes from pineapple (Ananas comosus) with documented mucolytic and anti-inflammatory action on respiratory mucosa. PMC evidence shows it has significant action in dissolving bronchial secretions and acts on sinonasal mucosa. It is used for bronchitis and sinusitis to reduce mucus via proteolytic degradation of mucus glycoproteins.
Bromelain, a cysteine protease complex from pineapple stems, has shown evidence in RCTs for reducing post-exercise muscle tenderness, swelling, and pain, and improving recovery of muscle function. German Commission E and ESCOP monographs validate its use for soft tissue inflammation reduction following trauma.
Bromelain, a protease enzyme from pineapple, has evidence from clinical studies for reducing post-exercise muscle soreness and improving muscle force recovery. Two studies with a protease supplement containing 99.9 mg bromelain showed improvements in muscle force recovery and a decrease in post-exercise muscle soreness after downhill treadmill running.
Bromelain, a proteolytic enzyme from pineapple, reduces nasal mucosal inflammation and thins mucus secretions implicated in post-nasal drip. Multiple clinical studies document faster recovery from sinusitis symptoms, including nasal discharge, compared to standard or placebo treatments. A 2014 pilot study in chronic rhinosinusitis patients showed improved total symptom scores and rhinoscopy scores. A 2023 PMC case-control study found significant reduction in rhinorrhea and nasal hyperemia when bromelain was added to standard therapy.
Bromelain is a proteolytic enzyme from pineapple approved by Germany's Commission E for post-surgical pain and healing. Multiple RCTs and a systematic meta-analysis demonstrate significant reductions in post-operative pain (SMD -0.49 to -0.52) after third molar surgery. A 200-patient Phase IV RCT confirmed improved wound healing and pain reduction after elective clean surgery.
Bromelain, a proteolytic enzyme complex from pineapple, has been included in post-COVID recovery clinical protocols for its anti-inflammatory, fibrinolytic, and mucolytic properties. An RCT (PMC8472462) tested systemic enzymes including bromelain for post-COVID fatigue, showing benefits in resolving post-viral inflammatory burden and improving fatigue outcomes.
Bromelain has documented clinical use in rheumatoid arthritis (RA) dating to early case reports, and has been recommended as an adjuvant therapeutic approach in chronic inflammatory and autoimmune diseases. It suppresses TNF-α–induced NF-κB and MAPK signaling, modulates TGF-β expression in RA patients, and reduces inflammatory cytokines in synovial fibroblasts. Multiple clinical studies and PMC reviews confirm evidence of benefit.
Bromelain, a proteolytic enzyme from pineapple, has evidence for reducing post-surgical swelling and fibrin-related scar tissue formation. It is used as an adjunct to scar treatment by breaking down fibrinous proteins and reducing inflammation that drives scarring.
Bromelain, a proteolytic enzyme from pineapple, is considered a principal proposed natural treatment for hay fever (allergic rhinitis) in authoritative integrative medicine references. It reduces nasal tissue edema, decreases mucus secretion, and exerts anti-inflammatory effects through multiple pathways relevant to seasonal allergies. EBSCO Research Starters lists it as one of the principal proposed natural treatments for seasonal allergies.
Bromelain, a proteolytic enzyme from pineapple stem, has anti-inflammatory and mucolytic properties relevant to seasonal respiratory health. Animal studies demonstrate reduced airway eosinophilic inflammation in asthma models. It is used clinically as an adjunct for nasal congestion and sinusitis and is frequently combined with quercetin in allergy protocols, also proposed to enhance quercetin bioavailability.
Bromelain, a proteolytic enzyme from pineapple, has multiple clinical trials supporting its use in sinusitis. A pilot study (n=12 chronic rhinosinusitis patients) showed improved symptom scores and quality of life with 500 FIP tablets. A trial of 116 children with acute sinusitis found faster recovery in the bromelain group (6.66 vs. 7.95 days). A Cochrane-indexed systematic review rated it as having encouraging evidence as an adjunctive treatment for acute rhinosinusitis.
Bromelain, a proteolytic enzyme from pineapple stem, is approved by the German Commission E for treatment of sinus and nasal swelling. A 2013 pilot study (PubMed PMID 24273953) found good tolerability and symptom improvement in chronic rhinosinusitis. A 2006 German study in children with acute sinusitis also reported therapeutic benefit.
Bromelain, a proteolytic enzyme from pineapple stem, has clinical and observational evidence for reducing pain, swelling, and bruising from soft tissue injuries including sprains. It is approved in Germany for traumatic musculoskeletal swelling. Double-blind studies support its anti-edematous effects in blunt injuries.
Bromelain has been evaluated in clinical studies for chronic sinusitis and upper respiratory tract infections, demonstrating immunomodulatory, mucolytic, and anti-inflammatory effects on nasal mucosa. A case-control study found that adding a bromelain-containing supplement to standard sinusitis treatment improved nasal hyperemia, rhinorrhea, and inflammatory markers (WBC, IgE, CRP). It is used clinically in Europe as part of combination products for sinusitis.
Bromelain has well-documented anti-edematous properties demonstrated in multiple clinical and preclinical studies. It degrades extracellular matrix proteins, reduces tissue fluid accumulation, inhibits bradykinin-mediated vascular permeability, and is used clinically for post-surgical and post-traumatic edema. Clinical trials in orthopedic surgery and CVI confirm significant reductions in edema.
Bromelain, a proteolytic enzyme complex from pineapple stems, reduces wound inflammation, promotes eschar removal, and has been used clinically as a topical debriding agent. RCT evidence supports its use in enzymatic debridement of burns and as an oral/topical anti-inflammatory in wound management.
Bromelain, the proteolytic enzyme from pineapple, is listed by the Arthritis Foundation among herbs with anti-inflammatory properties used for gout alongside turmeric and Devil's Claw. It inhibits COX-2, reduces bradykinin, and modulates cytokines (IL-1β, IL-6, TNF-α) central to MSU crystal-triggered gout inflammation. Clinical trials support its anti-inflammatory and analgesic activity in inflammatory joint conditions.
Bromelain (a proteolytic enzyme from pineapple) is listed among herbs and enzymes reported to be effective for dysmenorrhea and menstrual disorders in a PMC systematic review of chamomile for dysmenorrhea. Its anti-inflammatory properties via prostaglandin inhibition are relevant. Traditional and complementary medicine have used it for inflammatory gynecological pain.
Bromelain, a proteolytic enzyme from pineapple, is listed among proposed natural treatments for nosebleeds, based on the hypothesis that proteolytic enzymes may help stabilize capillaries. No clinical trials have directly evaluated bromelain for epistaxis; evidence is indirect and mechanistic.
Bromelain, a proteolytic enzyme complex from pineapple, is included in parasite cleanse protocols based on its ability to digest parasite cuticle proteins, paralleling papain's anthelmintic mechanism. Traditional tropical folk medicine uses pineapple for digestive and parasitic conditions.
Bromelain is a proteolytic enzyme complex from pineapple with antiedema effects similar to those used for varicose veins, supporting its proposed use. EBSCO Research Starters lists it as an 'other proposed natural treatment' for varicose veins, noting its antiedema properties and use in inflammation and tissue swelling. No direct clinical evidence exists for varicose veins specifically, but its mechanisms (fibrinolysis, anti-inflammation, edema reduction) align with CVI pathophysiology.
Body systems that Bromelain may help support.
Go back